Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Nephrology, Zhejiang University; Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, China.
Department of Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
EBioMedicine. 2021 Oct;72:103628. doi: 10.1016/j.ebiom.2021.103628. Epub 2021 Oct 12.
A disintegrin and metalloproteinases (ADAMs) family are proteolytic transmembrane proteases that modulate diverse cell functions and coordinate intercellular communication. ADAMs are responsible for regulating cell proliferation, differentiation, migration, and organ morphogenesis in kidney development. Abnormally activated ADAMs drive inflammation and fibrosis in response to kidney diseases such as acute kidney injury, diabetic kidney disease, polycystic kidney disease, and chronic allograft nephropathy. ADAM10 and ADAM17, known as the most characterized members of ADAMs, are extensively investigated in kidney diseases. Notably, ADAM proteases have the potential to be targets for developing novel treatment approaches in kidney diseases.
解整合素金属蛋白酶（ADAMs）家族是一类蛋白水解跨膜蛋白酶，可调节多种细胞功能并协调细胞间通讯。ADAMs 负责调节肾脏发育过程中的细胞增殖、分化、迁移和器官形态发生。异常激活的 ADAMs 可引发炎症和纤维化，从而导致肾脏疾病，如急性肾损伤、糖尿病肾病、多囊肾病和慢性移植肾肾病。ADAM10 和 ADAM17 作为 ADAMs 家族中最具特征性的成员，在肾脏疾病中得到了广泛研究。值得注意的是，ADAM 蛋白酶有可能成为肾脏疾病新治疗方法的靶点。
Zotero 插件
